Works by Binghe Xu

Results: 199
    1
    2
    3
    4
    5
    6
    7

    Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC.

    Published in:
    Oncologist, 2025, v. 30, n. 5, p. 1, doi. 10.1093/oncolo/oyaf048
    By:
    • Ueno, Naoto T;
    • Cottone, Francesco;
    • Dunton, Kyle;
    • Jacot, William;
    • Yamashita, Toshinari;
    • Sohn, Joohyuk;
    • Tokunaga, Eriko;
    • Prat, Aleix;
    • Tsurutani, Junji;
    • Park, Yeon Hee;
    • Rugo, Hope S;
    • Xu, Binghe;
    • Cardoso, Fatima;
    • Mitri, Zahi;
    • Mahtani, Reshma;
    • Aguilar, Cecilia Orbegoso;
    • Xiao, Feng;
    • Harbeck, Nadia;
    • Cameron, David A;
    • Modi, Shanu
    Publication type:
    Article
    8
    9

    First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.

    Published in:
    Oncologist, 2024, v. 29, n. 4, p. e514, doi. 10.1093/oncolo/oyad338
    By:
    • Piha-Paul, Sarina A;
    • Xu, Binghe;
    • Dumbrava, Ecaterina E;
    • Fu, Siqing;
    • Karp, Daniel D;
    • Meric-Bernstam, Funda;
    • Hong, David S;
    • Rodon, Jordi A;
    • Tsimberidou, Apostolia M;
    • Raghav, Kanwal;
    • Ajani, Jaffer A;
    • Conley, Anthony P;
    • Mott, Frank;
    • Fan, Ying;
    • Fan, Jean;
    • Peng, Peng;
    • Wang, Hui;
    • Ni, Shumao;
    • Sun, Caixia;
    • Qiang, Xiaoyan
    Publication type:
    Article
    10
    11
    12

    Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial.

    Published in:
    Nature Communications, 2025, v. 16, n. 1, p. 1, doi. 10.1038/s41467-025-56096-2
    By:
    • Xu, Binghe;
    • Zhang, Qingyuan;
    • Luo, Yang;
    • Tong, Zhongsheng;
    • Sun, Tao;
    • Shan, Changping;
    • Liu, Xinlan;
    • Yao, Yumin;
    • Zhao, Bing;
    • Wang, Shusen;
    • Zeng, Xiaohua;
    • Hu, Changlu;
    • Yan, Xi;
    • Wang, Xiaojia;
    • Jia, Hongyan;
    • Chen, Zhendong;
    • Qiu, Fuming;
    • Wu, Xinhong;
    • Zhang, Deyong;
    • Li, Tong
    Publication type:
    Article
    13
    14
    15
    16

    Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study.

    Published in:
    Breast Cancer (13406868), 2024, v. 31, n. 5, p. 858, doi. 10.1007/s12282-024-01600-7
    By:
    • Yamashita, Toshinari;
    • Sohn, Joo Hyuk;
    • Tokunaga, Eriko;
    • Niikura, Naoki;
    • Park, Yeon Hee;
    • Lee, Keun Seok;
    • Chae, Yee Soo;
    • Xu, Binghe;
    • Wang, Xiaojia;
    • Im, Seock-Ah;
    • Li, Wei;
    • Lu, Yen-Shen;
    • Aguilar, Cecilia Orbegoso;
    • Nishijima, Soichiro;
    • Nishiyama, Yuji;
    • Sugihara, Masahiro;
    • Modi, Shanu;
    • Tsurutani, Junji
    Publication type:
    Article
    17
    18
    19
    20
    21
    22
    23
    24

    In Reply.

    Published in:
    Oncologist, 2015, v. 20, n. 1, p. 88, doi. 10.1634/theoncologist.2014-0284
    By:
    • Xu, Binghe;
    • Seidman, Andrew;
    • Chan, Stephen
    Publication type:
    Article
    25
    26

    Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First-Line Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer.

    Published in:
    Oncologist, 2014, v. 19, n. 4, p. 348, doi. 10.1634/theoncologist.2014-0021
    By:
    • Moy, Beverly;
    • Neven, Patrick;
    • Lebrun, Fabienne;
    • Bellet, Meritxell;
    • Xu, Binghe;
    • Sarosiek, Tomasz;
    • Chow, Louis;
    • Goss, Paul;
    • Zacharchuk, Charles;
    • Leip, Eric;
    • Turnbull, Kathleen;
    • Bardy‐Bouxin, Nathalie;
    • Duvillié, Ladan;
    • Láng, István
    Publication type:
    Article
    27

    Bosutinib in Combination With the Aromatase Inhibitor Exemestane: A Phase II Trial in Postmenopausal Women With Previously Treated Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer.

    Published in:
    Oncologist, 2014, v. 19, n. 4, p. 346, doi. 10.1634/theoncologist.2014-0022
    By:
    • Moy, Beverly;
    • Neven, Patrick;
    • Lebrun, Fabienne;
    • Bellet, Meritxell;
    • Xu, Binghe;
    • Sarosiek, Tomasz;
    • Chow, Louis;
    • Goss, Paul;
    • Zacharchuk, Charles;
    • Leip, Eric;
    • Turnbull, Kathleen;
    • Bardy‐Bouxin, Nathalie;
    • Duvillié, Ladan;
    • Láng, István
    Publication type:
    Article
    28

    Analysis of Regional Timelines To Set Up a Global Phase III Clinical Trial in Breast Cancer: The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Experience.

    Published in:
    Oncologist, 2013, v. 18, n. 2, p. 134, doi. 10.1634/theoncologist.2012-0342
    By:
    • Metzger‐Filho, Otto;
    • Azambuja, Evandro;
    • Bradbury, Ian;
    • Saini, Kamal S.;
    • Bines, José;
    • Simon, Sergio D.;
    • Van Dooren, Veerle;
    • Aktan, Gursel;
    • Pritchard, Kathleen I.;
    • Wolff, Antonio C.;
    • Smith, Ian;
    • Jackisch, Christian;
    • Lang, Istvan;
    • Untch, Michael;
    • Boyle, Frances;
    • Xu, Binghe;
    • Baselga, Jose;
    • Perez, Edith A.;
    • Piccart‐Gebhart, Martine
    Publication type:
    Article
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50